Articles dans des revues avec comité de lecture (12)
  1. 1. Martins-Branco, D., Marta, G. N., Tecic Vuger, A., Debien, V., Ameye, L., Brandao, M., Punie, K., Loizidou, A., Willard-Gallo, K., Spilleboudt, C., Awada, A., Piccart-Gebhart, M., & de Azambuja, E. (2023). Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis. Journal of cancer research and clinical oncology, 149(7), 3075-3080. doi:10.1007/s00432-022-04185-w
  2. 2. Martins-Branco, D., Loizidou, A., Nader Marta, G., Tecic Vuger, A., Debien, V., Ameye, L., Brandão, M., Punie, K., Spilleboudt, C., Willard-Gallo, K., Awada, A., Piccart-Gebhart, M., & de Azambuja, E. (2022). Demographic and laboratory determinants of humoral immune responses and impact of different anti-SARS-CoV-2 vaccine platforms in patients with cancer: A systematic review and meta-analysis. Journal of clinical oncology, 40(16_suppl), 1543-1543. doi:10.1200/JCO.2022.40.16_suppl.1543
  3. 3. Nader Marta, G., Spilleboudt, C., Martins-Branco, D., Tecic Vuger, A., Debien, V., Ameye, L., Brandão, M., Punie, K., Loizidou, A., Willard-Gallo, K., Awada, A., Piccart-Gebhart, M., & de Azambuja, E. (2022). Impact of cancer diagnosis, stage, and systemic therapies on immunogenicity after COVID-19 vaccination in patients with cancer: A systematic review and meta-analysis. Journal of clinical oncology, 40(16_suppl), 1537-1537. doi:10.1200/JCO.2022.40.16_suppl.1537
  4. 4. Andreozzi, F., Massaro, F., Wittnebel, S., Spilleboudt, C., Lewalle, P., & Salaroli, A. (2022). New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy. International journal of molecular sciences, 23(7), 3887. doi:10.3390/ijms23073887
  5. 5. Goudsmit, A., Cubilier, E., Meert, A.-P., Aftimos, P., Stathopoulos, K., Spilleboudt, C., & Loizidou, A. (2021). Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study. Supportive care in cancer, 29(11), 6271-6278. doi:10.1007/s00520-021-06175-z
  6. 6. Lifrange, F., de Wind, R., Spilleboudt, C., Karfis, I., Van Gossum, A., & Demetter, P. (2021). Mantle cell lymphoma simulating inflammatory bowel disease. Acta Gastro-Enterologica Belgica (English ed.), 84(1), 125-127. doi:10.51821/84.1.852
  7. 7. Spilleboudt, C., De Wilde, V., Lewalle, P., Cabanne, L., Leclerc, M., Beckerich, F., Bories, D., Cardoso, S., Soares, M. P., Vokaer, B., Hougardy, J.-M., Flamand, V., Racapé, J., Abramowicz, M., Maury, S., & Le Moine, A. (2020). Donor-Derived Myeloid Heme Oxygenase-1 Controls the Development of Graft-Versus-Host Disease. Frontiers in immunology, 11, 579151. doi:10.3389/fimmu.2020.579151
  8. 8. Golstein, S., Muylle, K., Vercruyssen, M., Spilleboudt, C., de Wind, A., & Bron, D. (2018). Long-term follow-up of 2 patients treated with 90Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma. European journal of haematology, 101(3), 415-417. doi:10.1111/ejh.13087
  9. 9. Spilleboudt, C., Thibaut, P., Varlet, É. E., & Bron, D. (2018). Hyperleucocytose maligne ou bénigne? Revue médicale de Bruxelles, 39(4), 291-295.
  10. 10. Pistone, A., Maerevoet, M., Wittnebel, S., Vercruyssen, M., Spilleboudt, C., Buntinx, S., Bron, D., & Meuleman, N. (2016). Early Discontinuation of Lenalidomide in Patients with Relapsing or Refractory Multiple Myeloma: Predictive Factors for Stopping in the Real Life. Blood, 128(22), 4504-4504. doi:10.1182/blood.V128.22.4504.4504
  11. 11. Vokaer, B., Charbonnier, L.-M., Lemaitre, P., Spilleboudt, C., & Le Moine, A. (2013). IL-17A and IL-2-Expanded Regulatory T Cells Cooperate to Inhibit Th1-Mediated Rejection of MHC II Disparate Skin Grafts. PloS one, 8(10), e76040. doi:10.1371/journal.pone.0076040
  12. 12. Sadis, C., Detienne, S., Vokaer, B., Charbonnier, L.-M., Lemaitre, P., Spilleboudt, C., Delbauve, S., Kubjak, C., Flamand, V., Field, K. A., Goldman, M., Benghiat, F., & Le Moine, A. (2013). The Cholinergic Anti-Inflammatory Pathway Delays TLR-Induced Skin Allograft Rejection in Mice: Cholinergic Pathway Modulates Alloreactivity. PloS one, 8(11), e79984. doi:10.1371/journal.pone.0079984
    13. << Précédent 1 2 Suivant >>